Ecoatex is a biomaterials technology company that transforms agricultural and marine byproducts—nutshells, crop residues, and seaweed—into advanced cellulose materials, including cellulose, nanocellulose, and lignin.
These bio-based materials enable production of sustainable fibers, nonwovens, leathers, coatings, and composites for textiles, packaging, sportswear, and medical applications.
In hospitals and private practices, patient photos are essential for documentation, diagnosis, and outcomes tracking — yet most providers still use unsecured smartphone cameras and inconsistent processes.
This leads to HIPAA violations, lost or misfileed images, and inconsistent before-and-after documentation that diminishes clinical and marketing value.
Myosin Therapeutics is a clinical and R&D-stage biotech C-corp incorporated in Delaware and based in South Florida.
The company’s innovative science was developed collaboratively in the labs of Drs. Miller, Griffin, and Kamenecka at the Department of Molecular Medicine, Wertheim UF Scripps Institute for Biomedical Innovation & Technology—a University of Florida research institute dedicated to new treatments.
Nemea Therapeutics is advancing first-in-class oral small molecule therapies that inhibit mitochondrial sustenance to treat aggressive solid tumors.
The lead program targets mitochondrial RNA polymerase (POLRMT)—a long-elusive cancer hallmark. Many advanced cancers increase reliance on mitochondrial function after standard chemotherapy, making POLRMT inhibition a promising approach for safer, more effective therapy across a broad range of malignancies.
ThorafiX addresses Proximal Junctional Kyphosis (PJK), a debilitating complication affecting up to 46% of adult spinal deformity cases. PJK causes structural breakdown at the top of long spinal fusions, leading to vertebral collapse, severe pain, and costly revision surgeries.
Current approaches—pedicle screw-only constructs or soft-tissue preservation—fail to provide lasting biomechanical protection.
Every year, preventable deaths occur due to gaps in human monitoring—officers can’t watch every cell, and caregivers can’t reach every room. Traditional solutions rely on wearables, invasive cameras, or manual checks that compromise privacy or fail when devices are forgotten or refused.
Rahm Sensor Development addresses this critical need with contact-free radar, thermal, and intelligent video fusion processed entirely on-device.
DermiSense is a medical technology company revolutionizing diagnostic testing by offering a painless alternative to invasive blood draws.
Traditional blood sampling is expensive, resource-intensive, requires specialized training, and often causes patient anxiety—limiting frequent and decentralized testing.
SYMBIO-X Health is a Vanderbilt spin-out developing the first hardware-firmware co-designed wearable that delivers Doppler-grade cardiac valve metrics continuously at home—eliminating dependence on facility-based echo/MRI.
Kifa Therapeutics is a precision-neurology company developing first-in-class, mutant-selective kinase inhibitors to halt Parkinson’s disease at its genetic source.
Our lead program targets the G2019S mutation in LRRK2—the most common genetic cause of Parkinson’s—which drives neuronal toxicity through hyperactivation of the LRRK2 kinase pathway.
InTailor Bariatrics is advancing endoscopic automatic gastroplasty—an innovative technology that automates tissue acquisition, configuration, and fixation for consistent, reproducible outcomes and widespread physician adoption.
